Advisory: Give yourself extra time when travelling by car to Toronto General Hospital, Princess Margaret Cancer Centre, or Toronto Rehab University Centre. City of Toronto construction on University Ave. may cause delays.
At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
For more than 50 years, all new medications have been tested in patients using a similar approach, consisting of three consecutive phases of clinical trials. Each phase of testing produces data that helps to establish the new medication's effectiveness and safety.Subsequently, these data are used by regulatory agencies – such as Health Canada and the Food and Drug Administration (FDA) in the United States – to decide whether the new medication should be made available to all patients diagnosed with a particular disease.
In the past 15 years, the FDA and Health Canada have accelerated their approval process in an attempt to make new drugs to treat serious illnesses available faster. As a result, some anticancer drugs have been approved without being tested in Phase III randomized controlled trials (RCT).
The repercussions of approving drugs without supporting RCTs have not been examined thoroughly.
"Many researchers are concerned by the rapid approval process," said Dr.
Eitan Amir, a Clinical Researcher at the Princess Margaret Cancer Centre. "They are not convinced that a drug's benefit and potential toxicities in routine clinical practice can be predicted accurately without RCTs."
To address this, Dr. Amir led
a study evaluating the effect of RCTs on changes to drug labels. Because drug labels contain important safety information – such as dosage, side effects and other warnings – the changes made to labels can act as an indicator of potential problems with the approval process.
The study examined 59 anticancer drugs that were approved by the FDA between 2006 and 2016 and found that common side effects listed on drug labels were more likely to change for drugs that had not been tested in RCTs.
"Our findings suggest that rapid approval of drugs without supporting RCTs help patients receive new drugs faster at the expense of complete safety data," Dr. Amir says. "Healthcare professionals should be aware of this and should practice increased vigilance when prescribing such drugs."
This work was supported by The Princess Margaret Cancer Foundation.